A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

Sohye Kang, Andreas G. Bader, Peter K. Vogt · Proceedings of the National Academy of Sciences · 2005 · 824 citations · Full text

Medicine, Cancer Biology, Oncology +17

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Violeta Serra, Ben Markman, Maurizio Scaltriti et al. · Cancer Research · 2008 · 796 citations · Full text

Medicine, Oncology, Pharmacology +16

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

Xiaolin Wan, B Harkavy, Patrick J. Grohar et al. · Oncogene · 2006 · 747 citations

Life Sciences, Biochemistry, Molecular Biology +12